Researchers determine the differential risk of dementia among men and women based on the presence of obstructive sleep apnea.

Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Coya Therapeutics, Inc. (COYA – Research Report) today and set a price ...

On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in ...

Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker ...

Lecanemab Favors Early Aggregates. Fluorescently labeled lecanemab (green) bound most strongly to soluble Aβ aggregates ...

The research identified elevated levels of amyloid-β 42 (Aβ42) protein in participants with higher caffeine intake. This protein serves as a crucial marker in Alzheimer’s progression ...

A new study found that increased caffeine consumption may influence your risk of Alzheimer's or other forms of dementia. But experts still have questions on the association between caffeine and memory ...

Using single-molecule array technology, the levels of phosphorylated tau (p-tau217), amyloid-beta 40 (Aβ40), amyloid-beta 42 (Aβ42), glial fibrillary acidic protein, and neurofilament light (NfL) were ...

Those who drank less caffeine tended to have lower concentrations of a soluble form called Aβ42, with reduced ratios of Aβ42 with another form called Aβ40. They also had a reduced ratio between Aβ42 ...